

PREPARATION AND ANALYSIS OF NEW 1,3,5-TRISUBSTITUTED-2-PYRAZOLINES DERIVATIVE FOR THEIR ANALGESIC POTENTIAL

ABSTRACT

The goal of the study was to develop, synthesise, and characterise a novel 1,3,5-trisubstituted-2-pyrazolines derivative, as well as to assess its analgesic potential. The reaction of chalcone derivatives with 4-hydrazinylbenzene sulfonamide hydrochloride and phenyl hydrazine hydrochloride yielded 1,3,5-tri-substituted-2-pyrazolines derivatives. The IR, ¹HNMR, and mass spectrum analyses were used to characterise a total of sixteen substances. Analgesic activity of the proposed substances has been tested. The analgesic effect of the produced compounds was tested using two methods: the hot plate test technique and acetic acid induced writhing in mice. To compare the effectiveness, pentazocine and acetyl acetic acid were utilised as reference drugs. The hot plate test technique and acetic acid induced writhing in mice were used to assess the analgesic effect of the 16 produced chemical series A1-A8, and B1-B8. The evaluation's outcomes were viewed using Pentazocine and acetyl acetic acid as the standard drugs. In a 90-minute hot plate test, compounds A2 (10.30 s), A4 (9.45 s), A7 (11.65 s), and A8 (11.26 s) showed a delay in paw withdrawal latency time. Compounds B2 (9.10 s) and B7 (10.42 s) prolong the paw withdrawal latency time after 90 minutes in series B1-B8, reduce the pain feeling, and inhibit pain induced by heat methods. Compounds A2, A5, A6, A7, and A8 from Series A1-A8 showed 83.00, 76.01, 80.34, 86.99, 88.15 percent inhibition, substantially (p0.05 and p0.001, respectively), and decreased the number of wriths caused by 0.6 percent acetic acid at a dosage of 10 mg/kg. Acetylsalicylic acid (10 mg/kg) appears to be more successful in lowering the number of wriths, with a 99.0% reduction in the number of wriths (p0.001). B1, B3, and B4 have the least amount of active activity. These all finding suggest that these synthesized compounds have the potential as analgesic agent.

Keywords: Analgesic, Pyrazoline, Pentazocine, Hot plate method, Writhing

Introduction

Any member of the category of medications used to induce analgesia (pain alleviation) is referred to as an analgesic. [1] Analgesic medications affect the peripheral and central nerve systems in a variety of ways. Paracetamol, non-steroidal anti-inflammatory medications like salicylates, and opioid pharmaceuticals like morphine and opium are examples of narcotics,

which reversibly remove feeling. An analgesic is a medicine that reduces pain selectively by acting in the central nervous system (CNS) or on peripheral pain mechanisms without affecting consciousness.

Medicinal chemistry is virtually usually focused on drug development and discovery. Biochemistry, combinatorial chemistry, chemical biology, phytochemistry, pharmacology, Pharmacognosy, statistics, physical chemistry, and molecular biology have all been included into medicinal chemistry as a result of the focus on developing novel synthetic medicine molecules. [2] Medicinal chemists are also attempting to speed up the drug development process in order to uncover the lead molecule. Chalcone is a 1,3-diphenyl-2-propene-1-one compound with two aromatic rings connected by a three-carbon, -unsaturated carbonyl system. These are found in large quantities in edible plants and are thought to be precursors of flavonoids and isoflavonoids. Chalcones, which feature conjugated double bonds and a totally delocalized π -electron system on both benzene rings, have a low melting point due to their low intermolecular force. Molecules with this structure have comparatively low redox potentials and are more likely to conduct electron transfer processes. [3] The study of chemical properties, particularly the peculiarities of the behaviour of pyrazole derivatives and the clarification of their physicochemical features, has recently gotten a lot of interest. This allowed for the collection of fresh data that was crucial. Pyrazole derivatives have a long history of use as herbicides and insecticides in agriculture, as well as in the pharmaceutical sector as antipyretics and anti-inflammatory drugs. One of the first synthetic drugs was antipyrine. [4-8]. Various chalcone derivatives with suitable substitutions may be synthesised, which then undergo a cyclo-addition process with substituted hydrazine to provide desirable 1,3,5-tri substituted pyrazole derivatives. As a result, several chalcone derivatives were synthesised and employed as intermediates in the synthesis of 1,3,5 tri substituted pyrazole in the current work.

The objective of the paper was to design, synthesis and characterization of new 1,3,5-trisubstituted-2-pyrazolines derivative and evaluate for analgesic potential.

Material and method

Hi-media, New Delhi, provided the chemical 3'-methoxy-4'-hydroxy acetophenone. CDH (Chemical Drug House), New Delhi, India, provided benzaldehyde, 4-chlorobenzaldehyde, 4-bromobenzaldehyde, 4-nitrobenzaldehyde, 4-methylbenzaldehyde, 4-methoxybenzaldehyde, 4-ethylbenzaldehyde, and 4-(dimethyl amino)benzaldehyde. Sigma Aldrich, New Delhi, provided 4-hydrazinylbenzenesulfonamide hydrochloride and Phenyl hydrazine hydrochloride. Chemicals of synthetic grade were utilised in the experiments. In open glass

capillaries, the melting points of the produced compounds were determined. ALPHA (Bruker) FTIR Spectrometer was used to record IR spectra. Elemental analysis was carried out, and the results were determined to be within 0.4 percent of the theoretical values. On a Bruker Avance 400 spectrophotometer with a 400 MHz, 5mm multi-nuclear inverse probe head, low and high-temperature facility, and HRMAS accessory, ¹³C NMR spectra were acquired. ESI used mass spectrometers Jeol SX-102 (FAB) to record the spectra.


Chemistry

Present synthesis comprises

A. **Synthesis scheme-I:** Synthesis of chalcone of 3'-methoxy-4'-hydroxyacetophenone by Claisen Schmidt condensation

B. Synthesis scheme-II: Synthesis of 1,3,5- tri-substituted-2-pyrazolines derivatives.

Synthesis scheme-I: Synthesis of the chalcone of 3'-methoxy-4'-hydroxyacetophenone




3'-methoxy-4'-hydroxy-acetophenone

In the aforementioned procedure, an equimolar quantity (0.01 M) of 3-methoxy-4-hydroxy acetophenone (0.83g) was collected and combined with an equimolar quantity of benzaldehyde. In ethanol, the mixture was dissolved. The mixture was stirred for 5 minutes before adding a 50 percent aqueous potassium hydroxide solution slowly and stirring for 24 hours at room temperature. [9] The TLC was used to monitor the reaction's completion. The synthesis was then finished by pouring the liquid onto crushed ice and obtaining a solid result; however, if a solid product was not produced, it was acidified with dilute hydrochloric acid. The resulting solid was filtered, dried, and purified using a solvent system in column chromatography (hexane: ethyl acetate). In synthesis scheme-I, the reaction is shown. Infrared spectroscopy and proton NMR spectroscopy were used to analyse the produced compounds, and they were confirmed to be trustworthy with a likely structure. The obtained compounds were analysed using IR and ¹H NMR and found to have a structure that was compatible with what was predicted. 1500-1520 (C=C Quadrant of Ar), 1430-1470 (CH=CH), 1105 (C-F), 848 (C-Cl), 1015 (C-Br), and 1160 (O-H str) (OCH₃). These compounds further confirmed by proton NMR revealed the characteristic ethylenic protons of

the chalcone system in between δ 6.94 and 8.19 confirm the compound. The reaction was monitored by the TLC using Hexane: ethyl acetate as mobile phase.

Synthesis scheme-II: Synthesis of 1,3,5- tri-substituted-2-pyrazolines



The synthesised chalcone derivatives were combined in absolute alcohol with equimolar amounts of 4-hydrazinylbenzene sulfonamide hydrochloride and phenylhydrazine hydrochloride (0.005M) and a tiny amount of pyridine (0.01M) (5-7 ml). The reaction mixture was refluxed for 2-6 hours at 65°C. TLC was used to monitor the reaction, which used ethyl acetate:hexane as the mobile phase. The solvent was entirely evaporated before being placed into ice cold water and constantly stirred to convert the liquid form into a solid product, which yielded the synthesised product. [10] Scheme-II depicted the synthesis. This substance was filtered and dried under vacuum. Purified by column chromatography, the synthesised chemical was produced as a pale yellow solid colour powder. For phenyl hydrazine hydrochloride, the similar technique was followed, in which chalcone derivatives interacted with the phenyl hydrazine hydrochloride.

Pharmacological Evaluation

Analgesic activity

Determination of LD₅₀ value and acute toxicity

In this study, healthy and mature male albino Swiss rats weighing 120-150 g were employed. The animals were fasted for 24 hours and then separated into five groups of five. The test chemicals were given intraperitoneally at dosages of 10 mg, 100 mg, 1000 mg, and 2000 mg per kg body weight, suspended in sodium carboxymethyl cellulose solution (1%) Only the vehicle was given to the animals in the control group (1 percent sodium CMC). To record the

To protect the animals, a 15-second cut-off period was chosen. The mice were separated into thirty-four groups, each containing six animals.

Group 1: - Vehicle control (2% Tween 80).

Group 2: - Standard (Pentazocine 10 mg/kg, s.c.).

Group 3-18: Synthesized compounds (10 mg/kg, p.o.) respectively.

Acetic acid induced writhing in mice

Female Swiss albino mice (25–30g) were treated according to Collier et al 1963 's procedure. [20] Mice were given synthetic compounds and acetylsalicylic acid orally 60 minutes before receiving acetic acid solution at a rate of 10 ml/kg (0.6 percent, i.p.). [21] Over the course of 15 minutes, the number of abdominal constrictions (complete extension of both hind paws) was tallied.

The mice were divided into eleven groups of six mice each.

Group 1: - Vehicle control (2% Tween 80).

Group 2: - Standard (Acetylsalicylic acid 10 mg/kg p.o.).

Group 3-18: Synthesized compounds (10 mg/kg, p.o.) respectively.

The percent inhibition of writhing was calculated as follows: % Inhibition = $(VC - VT / VC) * 100$

Where, VT, number of writhes in drug treated mice; VC, number of writhes in control group mice.

RESULT AND DISCUSSION

Spectral analysis

The infrared spectra of the synthesized compounds showed characteristic absorption band between 3402 (O-H str.); 1592 (C=N); 1489 [C=C (Quadrant of Ar)]; 1174 (-C₆H₅); 1430 (CH=CH str.); 3418 (SO₂-NH str.); 1330, 1168 (S=O); 853 (C-Cl); 2938 (C-H aromatic), 853 (C-Cl), 1024 (C-Br); 1120 (C-F) and 1072 (OCH₃). In 1H-NMR spectra of the synthesized compounds represents the 6.21 (m, 2H, C₆H₅-NH₂), 6.84–7.34 (m, 3H, Ar-H); 8.52 (s, 1H, pyrazole-CH), 7.45-7.72 (d, 3H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd), 6.82-7.62 (m, 2H, Ar-H); 2.55 (m, 3H, C₆H₅ N(CH₃)₂), 3.81 (m, 3H, C₆H₅-OCH₃), 2.15 (m, 3H, C₆H₅-CH₃), 7.15 (bs, 2H, SO₂NH₂), 3.81 (m, 3H, C₆H₅-OCH₃) respectively. Methyl carbons were observed at 2.15 ppm.

All of the produced compounds' elemental analyses were within 0.4 percent of theoretical values. After nitration of the compounds, the existence of an aromatic ring was confirmed by the production of a strong sooty flame and the creation of an oily layer. Two significant peaks were identified in the FAB mass spectra. Using silica gel G and different solvent systems

such as hexane, thin layer chromatography (TLC) has been used to evaluate reactivity and purity of produced chemicals. For visualisation, ethyl acetate and iodine chambers were employed, with UV chambers being used in some situations. All these characterization parameter showed that the structure of the synthesized compounds were near to expected.

Compound A1: 4-(3-(4-hydroxy-3-methoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{22}H_{21}N_3O_4S$; Molecular weight: 423.48; TLC (Rf value): 0.45; Element (Found/Calc.)%: Nitrogen (9.85/9.92); Sulphur (7.59/7.57); Oxygen (15.10/15.11); IR (cm^{-1}): 3405 O-H str.; 1670 C=N; 1487 C=C; 1172 C_6H_5 ; 1428 CH=CH str.; 3415 SO_2NH str.; 1328 S=O; 2936 C-H; ¹H NMR (ppm): 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, -OCH₃), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd), 7.45 (d, 2H, Ar-H, J=8.6 Hz), 6.90–7.40 (m, 3H, Ar-H), 7.72–7.86 (m, 3H, Ar-H). FAB Mass (m/z): 423.13 (Quasi-molecular ion peak (M+H)).

Compound A2: 4-(5-(4-chlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{22}H_{20}ClN_3O_4S$; Molecular weight: 457.93; TLC (Rf value): 0.38; Element (Found/Calc.) %: Nitrogen (9.12/9.18); Sulphur (6.59/7.00); Oxygen (13.95/13.98); IR (cm^{-1}): 3400 O-H str.; 1668 C=N; 1484 C=C; 1170- C_6H_5 ; 1420 CH=CH str.; 3416 SO_2NH str.; 1325 S=O; 853 C-Cl; 2936 C-H; ¹H NMR: 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 8.52 (s, 1H, pyrazole-CH), 7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 6.90–7.40 (m, 3H, Ar-H), 7.45–7.88 (m, 3H, Ar-H); FAB Mass (m/z): 457.09 (Quasi-molecular ion peak (M+H)+)

Compound A3: 4-(5-(4-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{22}H_{20}BrN_3O_4S$; Molecular weight: 502.38; TLC (Rf value): 0.40; Element (Found/Calc.)%: Nitrogen (8.38/8.36); Sulphur (6.35/6.38); Oxygen (12.72/12.74); IR (cm^{-1}): 3409 O-H str.; 1672 C=N; 1491 C=C; 1176 C_6H_5 ; 1424 CH=CH str.; 3410 SO_2NH str.; 1325 S=O; 1020 C-Br; 2930 C-H; ¹H NMR: 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 8.52 (s, 1H, pyrazole-CH), 7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 6.90–7.40 (m, 3H, Ar-H), 7.56–7.68 (m, 3H, Ar-H); FAB Mass (m/z): 503.03 (Quasi-molecular ion peak (M+H)+)

Compound A4: 4-(5-(4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{22}H_{20}FN_3O_4S$; Molecular weight: 441.48; TLC (Rf value): 0.54; Element (Found/Calc.)%: Nitrogen (9.50/9.52); Sulphur (7.25/7.26); Oxygen (14.48/14.50); IR (cm^{-1}): 3410 O-H str.; 1670 C=N; 1484 C=C; 1170 C_6H_5 ; 1436 CH=CH str.; 3415 SO_2NH str.; 1326 S=O; 1118 C-F; 2929 C-H; ¹HNMR: 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH_3); , 8.52 (s, 1H, pyrazole-CH), 7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 6.90–7.40 (m, 3H, Ar-H), 7.30–8.10 (m, 3H, Ar-H); FAB Mass (m/z): 441.12 (Quasi-molecular ion peak (M+H)+)

Compound A5: 4-(3-(4-hydroxy-3-methoxyphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{22}H_{20}N_4O_6S$; Molecular weight: 468.48; TLC (Rf value): 0.30; Element (Found/Calc.)%: Nitrogen (11.94/11.96); Sulphur (6.82/6.84); Oxygen (20.47/20.49); IR (cm^{-1}): 3410 O-H str.; 1668 C=N; 1490 C=C; 1172 C_6H_5 ; 1428 CH=CH str.; 3418 SO_2NH str.; 1328 S=O; 1569 N=O str.; 1365 N-O str.; 2932 C-H; ¹HNMR: 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, C-3'- OCH_3); , 8.52 (s, 1H, pyrazole-CH), 7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 6.90–7.40 (m, 3H, Ar-H), 8.00–8.25 (m, 3H, Ar-H). FAB Mass (m/z): 468.11 (Quasi-molecular ion peak (M+H)+)

Compound A6: 4-(3-(4-hydroxy-3-methoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{23}H_{23}N_3O_4S$; Molecular weight: 437.51; TLC (Rf value): 0.64; Element (Found/Calc.)%: Nitrogen (9.58/9.60), Sulphur (7.32/7.33), Oxygen (14.60/14.63); IR (cm^{-1}): 3408 O-H str.; 1665 C=N; 1481 C=C; 1168 C_6H_5 ; 1426 CH=CH str.; 3424 SO_2NH str.; 1324 S=O; 1069 OCH_3 ; 2930 C-H; ¹HNMR: 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH_3); , 8.52 (s, 1H, pyrazole-CH), 6.95-7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 7.20–7.40 (m, 3H, Ar-H), 7.19–7.77 (m, 2H, Ar-H), 2.15 (m, 3H, $C_6H_5-CH_3$). FAB Mass (m/z): 437.14 (Quasi-molecular ion peak (M+H)+)

Compound A7: 4-(3-(4-hydroxy-3-methoxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenylsulfite

Molecular formula: $C_{23}H_{23}N_3O_5S$; Molecular weight: 453.51; TLC (Rf value): 0.23; Element (Found/Calc.)%: Nitrogen (9.25/9.27); Sulphur (7.02/7.07); Oxygen (17.62/17.64); IR (cm^{-1}): 3412 O-H str.; 1673 C=N; 1491 C=C; 1172 C_6H_5 ; 1428 CH=CH str.; 3422 SO_2NH str.; 1323 S=O; 1067 OCH_3 ; 2928 C-H; ¹HNMR (ppm): 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (6H, s, OCH_3); , 8.52 (s, 1H, pyrazole-CH), 6.95-7.45 (d, 2H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 7.20–7.40 (m, 3H, Ar-H), 7.35–7.55 (m, 2H, Ar-H). FAB Mass (m/z): 453.14 (Quasi-molecular ion peak (M+H)+)

Compound A8: 4-(5-(4-(dimethylamino)phenyl)-3-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenyl sulfite

Molecular formula: $C_{24}H_{26}N_4O_4S$; Molecular weight: 453.51; TLC (Rf value): 0.42; Element (Found/Calc.): Nitrogen (11.58/12.01); Sulphur (6.86/6.87); Oxygen (13.70/13.72); IR (cm^{-1}): 3407 O-H str.; 1665 C=N; 1493 C=C; 1170 C_6H_5 ; 1425 CH=CH str.; 3416 SO_2NH str.; 1327 S=O; 2932 C-H; ¹H NMR (ppm): 7.15 (bs, 2H, SO_2NH_2), 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH_3); 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd) 6.95-7.45 (d, 2H, Ar-H, J=8.6 Hz), 7.20-7.40 (m, 3H, Ar-H), 6.68-7.70 (m, 2H, Ar-H), 2.15 (m, 6H, $C_6H_5-N(CH_3)_2$). FAB Mass (m/z): 466.17 (Quasi-molecular ion peak (M+H)⁺). ¹NMR spectra was shown in Figure 2.

Compound B1: 4-(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxyphenol

Molecular formula: $C_{22}H_{20}N_2O_2$; Molecular weight: 344.41; TLC (Rf value): 0.38; Element (Found/Calc.): Nitrogen (8.10/8.13); Oxygen (9.27/9.29); IR (cm^{-1}): 3409 O-H str.; 1596 C=N; 1484 C=C; 1166 C_6H_5 ; 1432 CH=CH str.; 2934 C-H; ¹H NMR (ppm): 5.53 (1H, s, Ar-OH), 3.81 (3H, s, C-3'- OCH_3); 6.80-7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 7.10-7.51 (d, 3H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 7.45-7.62 (m, 3H, Ar-H). FAB Mass (m/z): 344.15 (Quasi-molecular ion peak (M+H)⁺)




Figure 1: ¹H NMR spectra of compound B2

Compound B2: 4-(5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxyphenol

Molecular formula: $C_{22}H_{19}ClN_2O_2$; Molecular weight: 378.85; TLC (Rf value): 0.42; Element (Found/Calc.): Nitrogen (7.38/7.39); Oxygen (8.42/8.45); IR (cm^{-1}): 3406 O-H str.; 1596 C=N; 1488 C=C; 1170 C_6H_5 ; 1428 CH=CH str.; 850 C-Cl; 2936 C-H; ¹H NMR (ppm): 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH_3); 6.80-7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 7.35-7.55 (d, 3H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd) 7.55-7.88 (m, 2H, Ar-

H). FAB Mass (m/z): 378.11 (Quasi-molecular ion peak (M+H)⁺). 1NMR spectra was shown in Figure 1.

Compound B3: 2-methoxy-4-(5-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl) phenol

Molecular formula: C₂₂H₁₉N₃O₄; Molecular weight: 389.40; TLC (R_f value): 0.40; Element (Found /Calc.)%: Nitrogen (10.78/10.79); Oxygen (16.42/16.43); IR (cm⁻¹): 3410 O-H str.; 1596 C=N; 1487 C=C; 1172 C₆H₅; 1428 CH=CH str.; 1025 C-Br; 2936 C-H; 1HNMR (ppm): 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd) 7.35-7.55 (d, 3H, Ar-H, J=8.6 Hz), 7.66-7.78 (m, 2H, Ar-H). FAB Mass (m/z): 389.14 (Quasi-molecular ion peak (M+H)⁺)

Compound B4: 4-(5-(4-fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy phenol

Molecular formula: C₂₂H₁₉FN₂O₂; Molecular weight: 362.40; TLC (R_f value): 0.45; Element (Found/Calc.)%: Nitrogen (7.70/7.73); Oxygen (8.82/8.83); IR (cm⁻¹): 3402 O-H str.; 1593 C=N; 1485 C=C; 1168 C₆H₅; 1424 CH=CH str.; 1115 C-F; 2932 C-H; 1HNMR: 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 7.45-7.62 (d, 3H, Ar-H, J=8.6 Hz), 3.60 (1H, dd); 5.36 (1H, dd), 7.35-8.15 (m, 2H, Ar-H). FAB Mass (m/z): 362.14 (Quasi-molecular ion peak (M+H)⁺)

Compound B5: 2-methoxy-4-(5-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl) phenol

Molecular formula: C₂₂H₁₉N₃O₄; Molecular weight: 389.40; TLC (R_f value): 0.32; Element (Found/Calc.)%: Nitrogen (10.76/10.79); Oxygen (16.40/16.43); IR (cm⁻¹): 3406 O-H str.; 1588 C=N; 1484 C=C; 1170 C₆H₅; 1428 CH=CH str.; 1576 N=O str.; 1366 N-O str.; 2935 C-H; 1HNMR: 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd), 7.45-7.62 (d, 3H, Ar-H, J=8.6 Hz), 8.05-8.32 (m, 2H, Ar-H). FAB Mass (m/z): 389.14 (Quasi-molecular ion peak (M+H)⁺).




Figure 2: ¹H NMR spectra of compound A8

Compound B6: 2-methoxy-4-(1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)phenol

Molecular formula: C₂₃H₂₂N₂O₂; Molecular weight: 358.43; TLC (R_f value): 0.36; Element (Found/Calc.)%: Nitrogen (7.82/7.82); Oxygen (8.90/8.93); IR (cm⁻¹): 3400 O-H str.; 1584C=N; 1491C=C; 1172 C₆H₅; 1425CH=CH str.; 2935 C-H; ¹H NMR: 5.53 (1H, s, Ar-OH), 3.81 (3H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd), 7.45-7.62 (d, 3H, Ar-H, J=8.6 Hz), 7.39-7.67 (m, 2H, Ar-H), 2.15 (m, 3H, C₆H₅-CH₃). FAB Mass (m/z): 358.17 (Quassi-molecular ion peak (M+H)⁺).

Compound B7: 2-methoxy-4-(5-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl) phenol

Molecular formula: C₂₃H₂₂N₂O₃; Molecular weight: 374.43; TLC (R_f value): 0.30; Element (Found/Calc.)%: Nitrogen (7.45/7.48); Oxygen (12.78/12.82); IR (cm⁻¹): 3412O-H str.; 1586C=N; 1485C=C; 1170C₆H₅; 1428CH=CH str.; 2930 C-H; ¹H NMR: 5.53 (1H, s, Ar-OH), 3.81 (6H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd), 7.45-7.62 (d, 3H, Ar-H, J=8.6 Hz), 7.05-7.50 (m, 2H, Ar-H). FAB Mass (m/z): 374.16 (Quassi-molecular ion peak (M+H)⁺).

Compound B8: 4-(5-(4-(dimethylamino)phenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxyphenol

Molecular formula: C₂₄H₂₅N₃O₂; Molecular weight: 387.47; TLC (R_f value): 0.48; Element (Found/Calc.)%: Nitrogen (10.82/10.84); Oxygen (8.20/8.26); IR (cm⁻¹): 3412O-H str.; 1594 C=N; 1491C=C; 1175C₆H₅; 1428CH=CH str.; 2935C-H; ¹H NMR: 5.53 (1H, s, Ar-OH), 3.81 (6H, s, OCH₃); 6.80–7.20 (m, 3H, Ar-H), 8.52 (s, 1H, pyrazole-CH), 3.60 (1H, dd); 5.36 (1H, dd), 7.45-7.62 (d, 3H, Ar-H, J=8.6 Hz), 6.82-7.61 (m, 2H, Ar-H), 2.15 (m, 6H, C₆H₅-N(CH₃)₂). FAB Mass (m/z): 387.19 (Quassi-molecular ion peak (M+H)⁺).

Pharmacological assessment

Acute toxicity test

Administration of 2000 mg/kg, p.o. of synthesized compounds did not produce any behavioral abnormalities and mortality. So the dose selected for further study was used is 10 mg/kg, p.o. for each compounds

Analgesic activity

Effect of oral administration of synthesized compounds on hot plate test in mice

In hot plate test, pentazocine (10 mg/kg, s.c.) significantly ($p < 0.001$) increased the paw withdrawal latency at 60 and 90 minutes. Onset of action was observed at 60 minutes of administration of pentazocine. However, In series A1-A8, shown delay the paw withdrawal latency time for compound A2 (10.30 s), A4 (9.45 s), A7 (11.65 s) and A8 (11.26 s) after 90 minutes. In series B1-B8, shown delay the paw withdrawal latency time for compound B2 (9.10 s) and B7 (10.42 s) after 90 minutes. In series C1-C8, shown delay the paw withdrawal latency time for compound C2 (9.15), C5 (10.42 s), C7 (11.54 s) and C8 (10.45 s) after 90 minutes and series D1-D8, shown delay the paw withdrawal latency time for compound D2 (10.32 s), D5 (5.30 s), D7 (12.45 s) and D8 (11.30 s) after 90 minutes. inhibit the pain sensation and inhibit pain produced by thermal means (Table 1).

Table 1: Effect of oral administration of synthesized compounds on hot plate test in mice

Treatment Groups	Paw withdrawal latency (Sec)						
	0 min	30 min	60 min	90 min	120 min	150 min	180 min
Vehicle Control	6.02 ± 0.45	5.45 ± 0.44	5.50 ± 0.62	4.83 ± 0.21	5.65 ± 0.55	5.83 ± 0.41	5.68 ± 0.58
Pentazocine (10 mg/kg)	5.65 ± 0.50	5.90 ± 0.38	9.15 ± 0.50***	11.33 ± 0.36***	7.98 ± 0.40**	6.08 ± 0.58	5.87 ± 0.40
A1 (10 mg/kg)	5.95 ± 0.58	5.03 ± 0.38	4.88 ± 0.67	6.10 ± 0.49*	4.35 ± 0.21	5.27 ± 0.58	5.10 ± 0.35
A2 (10 mg/kg)	4.73 ± 0.53**	5.58 ± 0.57**	8.55 ± 0.49***	10.30 ± 0.24***	6.77 ± 0.58** *	4.82 ± 0.38** *	5.78 ± 0.21**
A3 (10 mg/kg)	6.50 ± 0.58	4.98 ± 0.48	7.63 ± 0.46	9.15 ± 0.45	5.92 ± 0.45	5.55 ± 0.45	5.22 ± 0.45

mg/kg)		0.40	±0.51		±0.51**	±0.32	±0.37	0.60
A4	(10	4.90 ±	5.43	5.86	09.45	9.38	7.80	5.97 ±
mg/kg)		0.39**	±0.54**	±0.39**	±0.44**	±0.27**	±0.38**	0.69**
A5	(10	5.22 ±	5.35	7.96 ±0.49	8.20	6.20	5.20	5.27 ±
mg/kg)		0.38	±0.40		±0.51**	±0.47	±0.30	0.54
A6	(10	5.38 ±	5.85	8.65 ±0.36	8.32	6.62	5.17	5.72 ±
mg/kg)		0.43	±0.45		±0.57**	±0.57	±0.33	0.47
A7	(10	5.18 ±	6.55	9.02	11.65	9.28	6.55	5.60 ±
mg/kg)		0.58**	±0.53***	±0.34***	±0.37***	±0.60**	±0.26**	0.36**
		*				*	*	
A8	(10	5.30 ±	5.55	8.55	11.26	7.02	6.17	5.33 ±
mg/kg)		0.40**	±0.30**	±0.34***	±0.26***	±0.47**	±0.30**	0.41***
						*	*	
B1	(10	5.62 ±	5.32	6.26 ±0.25	7.15	5.68	5.30	5.55 ±
mg/kg)		0.44	±0.40		±0.30**	±0.45	±0.23	0.51
B2	(10	5.95 ±	5.03	6.63	9.10	5.35	5.27	5.10 ±
mg/kg)		0.58**	±0.38**	±0.67**	±0.49**	±0.21**	±0.58**	0.35**
B3	(10	4.73 ±	5.58	4.60 ±0.49	5.30	5.77	5.82	5.78 ±
mg/kg)		0.53	±0.57		±0.24	±0.58	±0.38	0.21
B4	(10	6.50 ±	4.98	7.63	6.15	5.92	5.55	5.22 ±
mg/kg)		0.40*	±0.51**	±0.46*	±0.51**	±0.32**	±0.37**	0.60**
B5	(10	4.90 ±	5.43	5.86 ±0.39	7.45	5.38	5.80	5.97 ±
mg/kg)		0.39	±0.54		±0.44*	±0.27	±0.38	0.69
B6	(10	5.22 ±	5.35	6.96 ±0.49	8.43	6.40	5.20	5.27 ±
mg/kg)		0.38	±0.40		±0.51**	±0.47	±0.30	0.54
B7	(10	5.38 ±	5.85	10.42±0.3	7.45	6.62	5.17	5.72 ±
mg/kg)		0.43**	±0.45**	6***	±0.57**	±0.57**	±0.33**	0.47**
		*				*	*	
B8	(10	5.18 ±	4.55±0.5	5.52	5.98	5.28	5.55	5.60 ±
mg/kg)		0.58**	3***	±0.34***	±0.37***	±0.60**	±0.26**	0.36**
		*				*		

Values are expressed as mean ± S.E.M.; n=6 mice per group. Two way ANOVA followed by Bonferroni post hoc test when compared with

vehicle control **p<0.01, ***p<0.001.

Effect of oral administration of synthesized compounds on acetic acid induced writhing in mice

Compounds A2 (83.00 percent), A5 (76.01 percent), A6 (80.34 percent), A7 (86.99 percent), and A8 (88.15 percent) from the Series A1-A8 have shown that the percent inhibition significantly ($p < 0.05$ and $p < 0.001$, respectively) reduced the number of wriths induced by 0.6 percent acetic acid at a dose of 10 mg/kg. When compared to the vehicle control group, chemicals B2 (72.25 percent), B7 (74.27 percent), and B8 (74.56 percent) showed the percent inhibition, significant ($p < 0.05$) reduction in the number of wriths. B1, B3, and B4 have the least amount of active activity. Acetylsalicylic acid (10 mg/kg) appears to be better effective in reducing the number of wriths, it significantly ($p < 0.001$) reduced the number of wriths by 99.0% (Figure 3).

Table 2: Effect of oral administration of synthesized compounds on acetic acid induced writhing in mice

Group No.	Treatment groups	Number of writhing	Percentage inhibition
1.	Vehicle control	68 ± 1.5	-
2.	Acetyl salicylic acid (10 mg/kg)	18 ± 2.1***	99.00
3.	A1	23 ± 1.1	65.31
4.	A2	11 ± 1.2	83.00
5.	A3	20 ± 0.8	70.52
6.	A4	22 ± 0.6	68.20
7.	A5	16 ± 0.7	76.01
8.	A6	14 ± 1.9	80.34
9.	A7	10 ± 2.2	86.99
10.	A8	08 ± 1.5	88.15
11.	B1	31 ± 1.1	54.04
12.	B2	19 ± 1.2	72.25
13.	B3	28 ± 1.7	59.53
14.	B4	29 ± 1.3	57.80
15.	B5	23 ± 1.8	65.02
16.	B6	21 ± 1.2	69.65
17.	B7	17 ± 1.4	74.27

18.	B8	16± 1.7	74.56
-----	----	---------	-------

Values are expressed as mean ± S.E.M.; n=6 mice per group. One way ANOVA followed by Dunnett's test when compared with vehicle control *p<0.05, ***p<0.001.




Figure 3: Percent inhibition of oral administration of synthesized compound on acetic acid induced writhing in mice

ANALGESIC ACTIVITY

(A) Hot plate method

Using a carrageenan-induced rat paw edoema rat model, the analgesic effect of several newly synthesised chemical series A1-A8, B1-B8, C1-C8, and D1-D8 was examined. The evaluation's outcomes were viewed using Pentazocine and acetyl acetic acid as the standard drugs. Pentazocine (10 mg/kg, s.c.) substantially (p0.001) enhanced paw withdrawal latency at 60 and 90 minutes in a hot plate test. The onset of activity was detected 60 minutes after the pentazocine was administered. However, after 90 minutes, compound A2 (10.30 s), A4 (9.45 s), A7 (11.65 s), and A8 (11.26 s) showed a delay in paw withdrawal latency time in series A1-A8. In series B1-B8, shown delay the paw withdrawal latency time for compound B2 (9.10 s) and B7 (10.42 s) after 90 minutes inhibit the pain sensation and inhibit pain produced by thermal means

(B) Acetic acid induced writhing in mice model

Compounds A2, A5, A6, A7, and A8 from Series A1-A8 showed 83.00, 76.01, 80.34, 86.99, 88.15 percent inhibition, substantially (p0.05 and p0.001, respectively), and decreased the number of wriths caused by 0.6 percent acetic acid at a dosage of 10 mg/kg. When compared to the vehicle control group, compounds B2, B7, and B8 showed 72.25, 74.27, and 74.56

percent inhibition, respectively, and a substantial ($p < 0.05$) reduction in the number of wriths. Acetylsalicylic acid (10 mg/kg) appeared to be more successful in reducing the number of wriths; it decreases the amount of wriths by 99.0 percent ($p < 0.001$).

CONCLUSION

The 1,3,5-pyrazoline derivatives were successfully synthesised and evaluated for analgesic activity in a mouse model, with compounds A2, A5, A6, A7, and A8 showing 83.00, 76.01, 80.34, 86.99, 88.15 percent inhibition, and compounds B2, B7, and B8 showing 72.25, 74.27, and 74.56 percent inhibition, respectively. Out of a total of 16 compounds, 8 are the most active. This evident that the presence of SO_2NH_2 is essential for the anti-inflammatory and analgesic activity and methyl, Chloro, methoxy and $\text{N}(\text{CH}_3)_2$ group attached at phenyl ring enhance the anti-inflammatory and analgesic activity. B1, B3, and B4 have the least amount of active activity. These all finding suggest that these synthesized compounds have the potential as analgesic agent.

REFERENCE

1. Sua S, Wang T, Duan J, Zhou W, Hua YQ, Tang YP, Qian DW. Anti-inflammatory and analgesic activity of different extracts of *Commiphora myrrha*. *J Ethno Pharm* 2011;134:251-258.
2. Kavitha CS, Hosamani KM, Seetharamareddy HR. In vivo analgesic and anti-inflammatory activities of newly synthesized Benzimidazole derivatives. *Eur J Med Chem* 2010;45:2048–2054.
3. Hoonur RS, Patil BR, Badiger DS, Vadavi RS, Gudasi KB, Dandawate PR, Ghaisas MM, Padhye SB, Nethaji M. Transition metal complexes of 3-aryl-2-substituted 1,2-dihydroquinazolin-4[3H]-one derivatives: New class of analgesic and anti-inflammatory agents. *Eur J Med Chem* 2010;45:2277–2282.
4. Deng JS, Chi CS, Huang SS, Shie PH, Lin TH, Huang GJ. Antioxidant, analgesic, and anti-inflammatory activities of the ethanolic extracts of *Taxillus liquidambaricola*. *J Ethno*2011;137:1161–1171.
5. Delporte C, Backhouse N, Inostroza V, Aguirre MC, Peredo N, Silva X, Negrete R, Miranda HF. Analgesic activity of *Ugnimolinae* [murtilla] in mice models of acute pain. *J Ethno*2007;112:162–165.
6. Amir M, Saifullah K, Akhter W. Design, synthesis and pharmacological evaluation of novelazole derivatives of aryl acetic acid as antiinflammatory and analgesic agents. *J EnzymInhib Med Chem* 2011;26:141–8.

7. Almasirad, M. Tajik, D. Bakhtiari. Synthesis and analgesic activity of N-arylhydrazone derivatives of mefenamic acid. *J Pharm Pharm Sci* 2016;8:254-258.
8. Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, Abdel-Aziz NI, El-Tahir KH, Shehatou GS, Abdel-Aziz AA. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives. *BioorgMedChem*2016;24:2032–2042.
9. Udipi RH, Bhat AR, Krishna K. Synthesis and investigation of some new pyrazoline derivatives for their antimicrobial, antiinflammatory and analgesic activities. *Ind J Heterocycl Chem* 1998;8:143–146.
10. Jadhav SY. PEG mediated synthesis and pharmacological evaluation of some fluoro substituted pyrazoline derivatives as antiinflammatory and analgesic agents. *Bioorg Med Chem Lett* 2013;23(9):2575-2578
11. Kenchappa R, Yadav D. Bodke. Synthesis, analgesic and anti-inflammatory activity of benzofuran pyrazole heterocycle. *Chem Data Coll* 2020;1-18.
12. Aziz H, Zahoor AF, Ahmad S. Pyrazole bearing molecules as bioactive scaffolds: a review. *J Chil Chem Soc* 2020;65:4746-4755
13. Chu M-J, Wang W, Ren Z-L, Liu H, Cheng X, Mo K, Wang L, Tang F, Lv X-H. Discovery of novel triazole-containing pyrazole ester derivatives as potential antibacterial agents. *Mol* 2019;24:1311-1322
14. Alam Md. J, Alam O, Khan SA, Naim J, Mohammad I, Deora GS. Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues. *Drug Design Dev Ther* 2016;10:3529-3543
15. Saad HA, Osman NA, Moustafa AH. Synthesis and Analgesic Activity of Some New Pyrazoles and Triazoles Bearing a 6,8-Dibromo-2-methylquinazoline Moiety. *Mol* 2011;16(10):187-201.
16. Sahu S K, Banerjee M, Samantray A, Behera C and Azam M A. Synthesis, analgesic, anti-inflammatory and antimicrobial activities of some novel pyrazoline derivatives. *Ther J Pharm Res* 2008;7(2):961-68.
17. Erden B, Murat S, Ergun BC, Baytas SN, Aypar E, Mustafa ARK. Synthesis of the Amide Derivatives of 3-[1-(3- Pyridazinyl)-5-phenyl-1H-pyrazole-3-yl]propanoic Acids as Potential Analgesic Compounds. *Turk J Chem* 2007;31:677-87
18. Amir M, Kumar H, Khan SA. Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents. *Bioorg Med Chem Lett* 2008;18(3):918-22.

19. Chavan RS, More HN, Bhosale AV. Synthesis and evaluation of analgesic and anti-inflammatory activities of a novel series of 3-(4, 5-dihydropyrazolyl)-indoles Int J Pharm Biomed Res2010;1(4):135-143.
20. OECD (2002). OECD test guidelines 404: acute dermal irritation and corrosion: Paris, France. https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oced/ocedtg_404.pdf
21. Collier H, Dineen C, Johnson A, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. British J Pharmacol 1963;32(2):295-310.

UNDER PEER REVIEW